trending Market Intelligence /marketintelligence/en/news-insights/trending/mmgjxnsway2zx03eh4qmiw2 content esgSubNav
In This List

OptimizeRx implements reverse stock split to qualify for Nasdaq listing

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


OptimizeRx implements reverse stock split to qualify for Nasdaq listing

OptimizeRx Corp. implemented a 1-for-3 reverse split of its common stock to qualify for listing on the Nasdaq Capital Market.

The reverse split reduced OptimizeRx's issued and outstanding common shares to 11,546,000 from 34,636,811.

Following the split, Nasdaq will review the company's listing application. OptimizeRx said there is no assurance the exchange will approve its application.

The company believes trading on Nasdaq will help increase its appeal to retail and institutional investors, expanding its shareholder base.

Rochester, Mich.-based OptimizeRx is an OTCQB-listed provider of digital health messaging for the pharmaceutical industry.